University of Toronto-ko ikertzaileekin lankidetzan egindako argitalpenak (5)

2022

  1. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

    The Lancet Oncology, Vol. 23, Núm. 8, pp. e374-e384

2019

  1. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

    The Lancet Oncology, Vol. 20, Núm. 6, pp. 862-876

2017

  1. Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study

    International Journal of Gynecological Cancer, Vol. 27, Núm. 1, pp. 50-58

2013

  1. Safety and efficacy of everolimus with exemestane vs. Exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2

    Clinical Breast Cancer, Vol. 13, Núm. 6, pp. 421-432.e8

2012

  1. Ovarian low-grade serous carcinoma: A comprehensive update

    Gynecologic Oncology, Vol. 126, Núm. 2, pp. 279-285